Objective: Amputation prevention efforts are often disjointed across health care providers and structured within silos of health care delivery. As a first step toward reducing disparities in limb preservation among peripheral artery disease (PAD) and diabetic patients across Ontario, we sought to compare regional differences in amputation rates.
Methods: From population-based administrative health data for Ontario, all PAD-or diabetes-related lower extremity minor and major amputations were identified between April 1, 2011, and March 31, 2016, among residents older than 40 years. Age-and sex-adjusted quarterly amputation rates were determined for each of the 14 Local Health Integration Network (LHIN) regions (Fig) in addition to crude rates in specified subgroups: age older than 70 years, female sex, lowest income quintile, dialysis patients, and patients living in long-term care.
Results: The adjusted rate of minor or major amputations ranged from 5.37 to 21.45 per 100,000 person-quarters. The adjusted rate of major amputations ranged from 2.47 to 12.62 per 100,000 person-quarters. LHINs with the most sparsely populated geographic area, many rural and remote communities, and low population density (LHINs 13 and 14) had the highest rates of amputations, whereas LHINs with most densely populated urban areas (LHINs 6 and 8) had the lowest rates of amputations. The same LHINs were high or low outliers whether looking at rates of any amputation, major amputations alone, diabetic patients alone, PAD patients alone, or the prespecified subgroups.
Conclusions: PAD-and diabetes-related amputation rates differ on the basis of geographic region. Further research is required to understand the basis for these regional differences in amputation rates across Ontario to help design and implement effective amputation prevention strategies.
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Status of Cardiac Markers in Patients With Peripheral Arterial Disease and Critical Limb Ischemia
Shubha Jain, 1 Hamzah Khan, 1 Sherri Afxentiou, 2 Rawand Abdin, hypothesize that patients with symptomatic PAD will express several diagnostic cardiac markers of CAD in the absence of acute coronary syndrome (ACS). Methods: We recruited 1200 PAD and non-PAD patients. We stratified patients on the basis of their clinical history, claudication distance, and ankle-brachial index into non-PAD, severe PAD, and CLI. In each group, 30 patients were matched on the basis of their age, sex, and cardiovascular risk factors. We performed enzyme-linked immunosorbent assay to measure the levels of troponin I, creatine kinase MB, N-terminal pro-Btype natriuretic peptide, oncostatin M, and fatty acid-binding protein 3 (FABP3). Patients with acute limb ischemia, ACS, heart or kidney failure, or arrhythmia were excluded. We considered cardiac markers with a P value < .05 significantly expressed.
Results: We detected cardiac markers in plasma of patients with PAD and CLI in the absence of ACS. FABP3 and N-terminal pro-B-type natriuretic peptide showed a positive correlation with the severity of PAD. FABP3 demonstrated the strongest correlation with PAD and CLI. The optimal cutoff point for FABP3 to predict CLI was estimated to be 3336 pg/mL (sensitivity of 91% with specificity of 100%).
Conclusions: Markers used to stratify CAD are elevated in patients with PAD and CLI in the absence of ACS. Our work also demonstrates a direct correlation between these markers and severity of PAD. FABP3, a protein involved in intracellular transport of long-chain fatty acids, demonstrated the strongest correlation with PAD, indicating an important role played by lipid metabolism in the development of PAD. We are currently investigating the pathophysiology of FABP3 and its role in CLI.
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Role of Drug-Coated Balloons in Femoropopliteal
Methods: This retrospective study evaluated the patients who underwent DCB angioplasty for femoropopliteal PAD at our center between 2010 and 2016, with at least 1 year of follow-up. Of 424 patients with DCB-treated femoropopliteal disease, 152 were classified as TASC II type C or D. Demographics and comorbidities including age, sex, smoking status, hypertension, diabetes, and dialysis were recorded, alongside intervention details. Freedom from target lesion revascularization (TLR) within 1 year of interventionddefined as requiring bypass surgery or repeated percutaneous endovascular interventiondwas the primary outcome. Secondary outcomes included major above-knee or belowknee amputation and death.
Results: We analyzed 152 patients, excluding 13 because of immediate reintervention, amputation, bypass surgery, or death within 30 days of intervention. Of these 139 patients, 92 (66%) were type C and 47 (34%) were type D, with a mean treated lesion length of 18 6 6 cm; 75% were current or past smokers, 83% had hypertension, 63% had diabetes, and 5% were on dialysis. The dominant indication (45%) was severe claudication (Rutherford class 3), the remaining 55% being Rutherford class 4 to 6. De novo lesions made up 62% of cases, with in-stent stenosis or occlusions and recurrent stenosis each representing 19%; 27% of lesions were simultaneously treated with a short bare stent or drug-eluting stent, and 46% had multifocal disease treated as part of the procedure. At 1 year, 2% of patients had major amputation, and mortality was 12%. TLR at 1 year was 24% (33/139; Fig) .
Conclusions: Freedom from TLR in this cohort of patients with TASC II types C and D PAD was found to be 88% at 6 months and 76% at 12 months. Our initial results show that DCBs have a promising role in management of complex femoropopliteal disease. 
